ConductScience.org, home

Paper41003906

Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis.

Jamialahmadi T and 6 others. Curr Atheroscler Rep, 2025. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis. Papers, record 41003906. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41003906

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis.
PubMed
Journal
Curr Atheroscler Rep
PubMed
Year
2025
PubMed
Publication types
Journal Article, Meta-Analysis, Review
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2026-11-05
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jamialahmadi TTannaz
2Mirhadi EElaheh
3Reiner ŽŽeljko
4Abass KSKasim Sakran
5Almahmeed WWael
6S Virani SSalim
7Sahebkar AAmirhossein

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
PioglitazoneMajor topic
Lipoprotein(a)Major topic
Hypoglycemic AgentsMajor topic
Diabetes Mellitus, Type 2Major topic
Humans

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119835463Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.Curr Med Res Opin2009https://conductscience.org/library/papers/19835463PubMed
240231787Experimental Models to Investigate PNPLA3 in Liver Steatosis.Liver Int2025https://conductscience.org/library/papers/40231787PubMed
320965889Lipoprotein(a) as a cardiovascular risk factor: current status.Eur Heart J2010https://conductscience.org/library/papers/20965889PubMed
426171320Pioglitazone and Endothelial Dysfunction: Pleiotropic Effects and Possible Therapeutic Implications.Sci Pharm2014https://conductscience.org/library/papers/26171320PubMed
522998429Lipoprotein(a): resurrected by genetics.J Intern Med2013https://conductscience.org/library/papers/22998429PubMed
636036785Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.Eur Heart J2022https://conductscience.org/library/papers/36036785PubMed
722686416Basal insulin and cardiovascular and other outcomes in dysglycemia.N Engl J Med2012https://conductscience.org/library/papers/22686416PubMed
817275945Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders.Diabetes Res Clin Pract2007https://conductscience.org/library/papers/17275945PubMed
924710641
Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus.
Exp Clin Endocrinol Diabetes2014https://conductscience.org/library/papers/24710641PubMed
1028057658Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.BMJ Open2017https://conductscience.org/library/papers/28057658PubMed
1132466884Familial Hypercholesterolemia and Lipoprotein(a): Unraveling the Knot That Binds Them.J Am Coll Cardiol2020https://conductscience.org/library/papers/32466884PubMed
1240066493Impact of diabetes on risk of major adverse cardiovascular events associated with lipoprotein(a) levels in patients with established atherosclerotic cardiovascular disease.Eur J Prev Cardiol2025https://conductscience.org/library/papers/40066493PubMed
1318690882Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors.Curr Clin Pharmacol2008https://conductscience.org/library/papers/18690882PubMed
1437442270Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: Is there a role for statin therapy?Metabolism2023https://conductscience.org/library/papers/37442270PubMed
1539270008Peroxisome Proliferator-Activated Receptor Gamma Regulates Interleukin-6-Induced Lipoprotein (a) Gene Expression in Human HepG2 Cells.J Cardiovasc Pharmacol2024https://conductscience.org/library/papers/39270008PubMed
1621207250Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial.Lipids2011https://conductscience.org/library/papers/21207250PubMed
1738418000Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease.J Am Coll Cardiol2024https://conductscience.org/library/papers/38418000PubMed
1816861090
Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Clin Ther2006https://conductscience.org/library/papers/16861090PubMed
1920977573Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?Diabetes Obes Metab2010https://conductscience.org/library/papers/20977573PubMed
2025713100IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans.J Lipid Res2015https://conductscience.org/library/papers/25713100PubMed

See all 42 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42985587Lipoprotein(a) and Prognostic Nutritional Index Levels Exhibit Interactive and Joint Effects on Mortality Risk in Patients With Coronary Artery Disease: Findings From a Real-World Study.Rev Cardiovasc Med2026https://conductscience.org/library/papers/42985587PubMed
42111957The Impact of Current and Emerging Therapies on Lipoprotein(a).Eur Cardiol2026https://conductscience.org/library/papers/42111957PubMed
41923065Lipoprotein(a) levels in Finnish adults: distribution and associations with other cardiovascular risk factors and their awareness and control.Lipids Health Dis2026https://conductscience.org/library/papers/41923065PubMed
41680637Positive association of lipoprotein(a) and the prevalence of lower extremity arterial disease in MASLD: a cross-sectional study.BMC Cardiovasc Disord2026https://conductscience.org/library/papers/41680637PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene
LPA4018PubTator's text mininghttps://conductscience.org/library/genes/4018NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41003906

GET https://conductscience.org/api/papers/v1/41003906/references?page=2